Lupin, largest manufacturer of Tuberculosis drugs in the world, has reported results for the quarter ended June 30, 2011.
The company’s net profit for the quarter declined by 53.79% at Rs 72.75 crore as compared to Rs 157.42 crore for the similar quarter of the previous fiscal. Its total income has increased by 9.54% for the quarter under review at Rs 1106 crore for the quarter under review against Rs 1009.69 crore for the June quarter of the FY11.
On consolidated basis, the Group’s net profit after tax for the quarter ended June 30, 2011 has increased by 7.02% at Rs 210.08 crore as compared to Rs 196.30 crore for the quarter ended June 30, 2010. Its total income has increased by 17.51% from Rs 1335.11 crore for the June quarter last year to Rs 1568.92 crore for the quarter under review.
